The overall point is that higher microRNA expression of these oncogenic factors that directly target PTEN in osteosarcoma has a greater impact on the PI3K/AKT pathway, which ultimately leads to higher malignancy and worse prognosis for patients with osteosarcoma. This evidence concerns the gene AKT1 and osteosarcoma.